logo
Here's Why Federated Hermes (FHI) is a Strong Momentum Stock

Here's Why Federated Hermes (FHI) is a Strong Momentum Stock

Yahoo19-05-2025

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors.
Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to use the Zacks Style Scores, which are indicators that rate stocks based on three widely-followed investing types: value, growth, and momentum.
Different than value or growth investors, momentum-oriented investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
Headquartered in Pittsburgh, PA, Federated Hermes, Inc. is a global asset manager with $829.6 billion in AUM as of Dec. 31, 2024. It was formed from the merger between Federated Investors and Hermes Investment Management.
FHI sits at a Zacks Rank #3 (Hold), holds a Momentum Style Score of A, and has a VGM Score of A. The stock is up 1.3% and up 15.4% over the past one-week and four-week period, respectively, and Federated Hermes has gained 32.2% in the last one-year period as well. Additionally, an average of 933,669.88 shares were traded over the last 20 trading sessions.
A company's earnings performance is important for momentum investors as well. For fiscal 2025, four analysts revised their earnings estimate higher in the last 60 days for FHI, while the Zacks Consensus Estimate has increased $0.20 to $4.30 per share. FHI also boasts an average earnings surprise of 13.1%.
Investors should take the time to consider FHI for their portfolios due to its solid Zacks Ranks, notable earnings metrics, and impressive Momentum and VGM Style Scores.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Federated Hermes, Inc. (FHI) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Increases to some taxes and fees in New Mexico go into effect on July 1
Increases to some taxes and fees in New Mexico go into effect on July 1

Yahoo

time23 minutes ago

  • Yahoo

Increases to some taxes and fees in New Mexico go into effect on July 1

NEW MEXICO (KRQE) – Some tax and fee changes throughout the state are soon going into effect. On July 1, the excise tax rate on cannabis will go up from 12% to 13%. Then every year after, the rate will increase until it reaches 18 percent in 2030. New resolution looks to add more properties to Nob Hill redevelopment project The New Mexico Taxation and Revenue Department said sales tax increased in several towns, including Roswell, Texico, Las Cruces, and Portales. Also, workers' comp fees will go up 25 cents for employers and employees. The 911 emergency surcharge, which funds dispatch operations statewide, is now $1. The telecommunications relay surge is now 1.36%. That revenue will go to the 988 crisis line. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Why CoreWeave, Inc. (CRWV) Skyrocketed Today
Why CoreWeave, Inc. (CRWV) Skyrocketed Today

Yahoo

timean hour ago

  • Yahoo

Why CoreWeave, Inc. (CRWV) Skyrocketed Today

We recently published a list of . In this article, we are going to take a look at where CoreWeave, Inc. (NASDAQ:CRWV) stands against other Wednesday's best-performing stocks. CoreWeave rallied for a fourth consecutive day on Wednesday, jumping 8.39 percent to close at $163.10 apiece following the unveiling of record-breaking performance results using Nvidia Corp.'s latest Grace Blackwell chips. In a statement, CoreWeave, Inc. (NASDAQ:CRWV) said that it used 2,496 Nvidia GPUs on its AI-optimized cloud platform, making its submission the largest-ever benchmarked under MLPerf. A close-up of a digital cloud, signifying the expansive reach of the software-as-a-service solution. CoreWeave, Inc. (NASDAQ:CRWV) said that the test was 34x larger than the only other submission from a cloud provider. 'AI labs and enterprises choose CoreWeave because we deliver a purpose-built cloud platform with the scale, performance, and reliability that their workloads demand,' said CoreWeave, Inc. (NASDAQ:CRWV) Chief Technology Officer Peter Salanki. 'These MLPerf results reinforce our leadership in supporting today's most demanding AI workloads,' he added. The unveiling followed the company's new $7-billion deal with Applied Digital Corporation (NASDAQ:APLD), which covered two 15-year lease agreements, under which the latter will deliver 250 megawatts of critical IT load to host its artificial intelligence (AI) and high-performance computing (HPC) infrastructure at its Ellendale, North Dakota data center campus. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.

Why ImmunityBio, Inc. (IBRX) Skyrocketed Today
Why ImmunityBio, Inc. (IBRX) Skyrocketed Today

Yahoo

timean hour ago

  • Yahoo

Why ImmunityBio, Inc. (IBRX) Skyrocketed Today

We recently published a list of . In this article, we are going to take a look at where ImmunityBio, Inc. (NASDAQ:IBRX) stands against other Wednesday's best-performing stocks. ImmunityBio extended its winning streak to a fifth consecutive day on Wednesday, jumping 8.1 percent to finish at $2.93 apiece as investors cheered the Food and Drug Administration's (FDA) green light for the company to expand the access of its Anktiva treatment to patients with solid tumors. According to ImmunityBio, Inc. (NASDAQ:IBRX), it was granted by the FDA to treat lymphopenia in adult patients with refractory or relapsed solid tumors. 'Lymphopenia has long been recognized as a major driver and predictor of early mortality in cancer—yet until now, it has remained unaddressed,' said ImmunityBio, Inc. (NASDAQ:IBRX) founder and Executive Chairman Patrick Soon-Shiong. A technician analyzing natural killer cells, as part of an immune system study and research into therapeutical agents. 'This FDA authorization allows all patients with solid tumors suffering from immune collapse following first-line therapy of chemo, radiation, or immunotherapy to access ANKTIVA. The survival benefit we observed at ASCO 2025 in 3rd to 6th line advanced metastatic pancreatic cancer confirms that restoring lymphocyte levels, rather than depleting them, can change the course of disease.' Following the announcement, the company earned a 'buy' recommendation and a price target of $8 from investment firm HC Wainwright. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store